Cargando…
Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial
INTRODUCTION: Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease (ESRD) in the USA and worldwide. Recent experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) may decrease progression of chronic kidney disease....
Autores principales: | Leehey, David J, Carlson, Kimberly, Reda, Domenic J, Craig, Ian, Clise, Christina, Conner, Todd A, Agarwal, Rajiv, Kaufman, James S, Anderson, Robert J, Lammie, Douglas, Huminik, Jeffrey, Polzin, Linda, McBurney, Conor, Huang, Grant D, Emanuele, Nicholas V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370537/ https://www.ncbi.nlm.nih.gov/pubmed/34400461 http://dx.doi.org/10.1136/bmjopen-2021-053019 |
Ejemplares similares
-
Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials
por: Wei, Ling, et al.
Publicado: (2021) -
Effect of the COVID-19 Pandemic on Rates and Epidemiology of Clostridioides difficile Infection in One VA Hospital
por: Wright, Lorinda M., et al.
Publicado: (2023) -
VEGF‐A(165)b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF‐A splice isoforms from the kidney
por: Stevens, Megan, et al.
Publicado: (2017) -
Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial
por: Chan, Kam Wa, et al.
Publicado: (2016) -
RAAS inhibitors directly reduce diabetes‐induced renal fibrosis via growth factor inhibition
por: Koszegi, Sandor, et al.
Publicado: (2018)